Belgium In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2012

Global Markets Direct, December 2008, Pages: 139

Belgium In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2012

Summary

This report is an essential source for in-depth information and data relating to the Belgium In vitro diagnostic dvices market. It also offers detailed and comprehensive coverage of market revenue, distribution and company share information; and latest news, financial deals and pipeline products information of each of the key sub-segments of the in vitro diagnostics market market in Belgium

Scope

- The report provides in vitro diagnostics information broken down into detailed categories and segments in Belgium.
- Total revenues, end users
- Market shares of all the key competitors.
- Key pipeline products that are set to shape the market, broken down by sector.
- Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis.
- Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
- Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
- Key mergers and acquisitions, partnerships, private equity investments and IPOs.
- Customer, hospitals and physicians data.

Reasons to buy

- Gain a strong understanding of the in vitro diagnostics devices market in Belgium.
- Evaluate and compare the attractiveness of the market in the country.
- Identify growth segments and opportunities in each industry sector within the country.
- Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.
- Analyze the competitiveness of the market in the country and identify hotspots.
- Develop strategies based on the latest product, brand, expansion and research and development news in the country.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.
- Identify and analyze the strengths and weaknesses of the industry incumbents in the country.

1 2
1.1 List of Tables 9
1.2 List of Figures 11
2 Introduction 13
2.1 What Is This Report About? 13
3 Definitions of Markets Covered in the Report 14
3.1 In Vitro Diagnostics Devices 14
3.2 Clinical Chemistry Test Reagents 14
3.2.1 Laboratory Reagents 14
3.2.2 Clinical Chemistry Calibrators and Controls 14
3.2.3 Clinical Chemistry Rapid Tests 14
3.3 Immunochemistry Test Reagents 14
3.3.1 Disease Specific Markers 14
3.3.2 Disease Specific Test Reagents 15
3.3.3 Drug Related Testing Reagents 15
3.3.4 Hormone Related Testing Reagents 16
3.3.5 Immunochemistry Calibrators and Controls 16
3.3.6 Immunochemistry Rapid Tests 16
3.4 Blood Test Reagents 17
3.4.1 Hematology Test Reagents 17
3.4.2 Hemostasis Test Reagents 17
3.4.3 Tissue Typing Reagents 18
3.4.4 Monoclonal Antibodies 18
3.4.5 Cytokines and Immunomodulators 18
3.4.6 Histology and Cytology Reagents 18
3.5 Microbiology Test Reagents 18
3.5.1 Bacteriology Test Reagents 18
3.5.2 Microbiology Calibrators and Controls 19
3.5.3 Microbiology Rapid Tests 19
3.6 Infectious Immunology Test Reagents 19
3.6.1 Bacteriology 19
3.6.2 Virology 19
3.6.3 Parasitology 20
3.6.4 Infectious Immunology Calibrators and Controls 20
3.6.5 Infectious Immunology Rapid Tests 20
3.7 Genetic Test Reagents 20
3.8 Self Testing 20
3.9 Instruments 20
4 Healthcare Sector Review 21
4.1 Healthcare Expenditure 21
4.2 Healthcare Infrastructure 23
4.2.1 Healthcare Personnel Data 24
4.2.2 Healthcare Facilities Data 25
4.3 Healthcare Policy 26
5 Regulation System 28
5.1 Medical Equipment Approval Process 28
5.1.1 Classification 29
5.1.2 Conformity Assessment Process 38
5.2 Notification Fee 42
6 Pricing and Reimbursement 43
6.1 Reimbursement Policies 43
7 Distribution Structure 44
8 In Vitro Diagnostics In Belgium 45
8.1 In Vitro Diagnostics Cross Country Comparison (2000-2012) 45
8.2 In Vitro Diagnostics, Belgium, Overall Revenues ($ mn), 2000-2012 46
8.3 In Vitro Diagnostics, Belgium Company share (2006-2007) 52
9 Blood Test Reagents In Belgium 53
9.1 Blood Test Reagents Overall Revenue (2000-2012) 53
9.1.1 Haematology Test Reagents Overall Revenues (2000-2012) 57
9.1.2 Hemostasis Test Reagents Overall Revenues (2000-2012) 59
9.2 Blood Test Reagents Distribution Share (2006-2007) 61
9.3 Blood Test Reagents, Belgium, Company Share (2006-2007) 62
10 Clinical Chemistry Test Reagents In Belgium 63
10.1 Clinical Chemistry Test Reagents Overall Revenue (2000-2012) 63
10.2 Clinical Chemistry Test Reagents Distribution Share (2006-2007) 65
10.3 Clinical Chemistry Test Reagents, Belgium, Company Share (2006-2007) 66
11 Genetic Test Reagents In Belgium 67
11.1 Genetic Test Reagents Overall Revenue (2000-2012) 67
11.2 Genetic Test Reagents Distribution Share (2006-2007) 69
11.3 Genetic Test Reagents, Belgium, Company Share (2006-2007) 70
12 Immunochemistry Test Reagents In Belgium 71
12.1 Immunochemistry Test Reagents Overall Revenue (2000-2012) 71
12.1.1 Disease Specific Markers Overall Revenues (2000-2012) 75
12.1.2 Disease Specific Test Reagents Overall Revenues (2000-2012) 77
12.1.3 Drug Related Testing Reagents Overall Revenues (2000-2012) 79
12.1.4 Hormone Related Testing Reagents Overall Revenues (2000-2012) 81
12.2 Immunochemistry Test Reagents Distribution Share (2006-2007) 83
12.3 Immunochemistry Test Reagents, Belgium, Company Share (2006-2007) 84
13 Infectious Immunology Test Reagents In Belgium 85
13.1 Infectious Immunology Test Reagents Overall Revenue (2000-2012) 85
13.1.1 Virology Overall Revenues (2000-2012) 89
13.2 Infectious Immunology Test Reagents Distribution Share (2006-2007) 91
13.3 Infectious Immunology Test Reagents, Belgium, Company Share (2006-2007) 92
14 Instruments In Belgium 93
14.1 Instruments Overall Revenue (2000-2012) 93
14.2 Instruments Distribution Share (2006-2007) 95
14.3 Instruments, Belgium, Company Share (2006-2007) 96
15 Microbiology Test Reagents In Belgium 97
15.1 Microbiology Test Reagents Overall Revenue (2000-2012) 97
15.1.1 Bacteriology Test Reagents Overall Revenues (2000-2012) 98
15.2 Microbiology Test Reagents Distribution Share (2006-2007) 100
15.3 Microbiology Test Reagents, Belgium, Company Share (2006-2007) 101
16 Self Testing In Belgium 102
16.1 Self Testing Overall Revenue (2000-2012) 102
16.2 Self Testing Distribution Share (2006-2007) 104
16.3 Self Testing, Belgium, Company Share (2006-2007) 105
17 F. Hoffmann-La Roche Ltd. Company Profile 106
17.1 Company Overview 106
17.2 Value Chain Analysis 106
17.2.1 Manufacturing 107
17.2.2 Product Development 107
17.2.3 Sales and Marketing 108
18 Abbott Laboratories Company Profile 110
18.1 Company Overview 110
18.2 Value Chain Analysis 110
18.2.1 Manufacturing 111
18.2.2 Product Development 111
18.2.3 Sales and Marketing 112
18.2.4 Abbott Laboratories Pipeline Products by Equipment Type 112
18.2.5 Abbott Laboratories Pipeline Products by Development Stage 112
18.2.6 Abbott Laboratories Pipeline Products by Therapy Area 113
18.2.7 Abbott Laboratories Pipeline Products by Clinical Trials 113
18.2.8 Abbott Laboratories Pipeline Products by News Summary 113
19 bioMerieux S.A. Company Profile 114
19.1 Company Overview 114
19.2 Value Chain Analysis 114
19.2.1 Manufacturing 115
19.2.2 Product Development 115
19.2.3 Sales and Marketing 116
20 Beckman Coulter, Inc. Company Profile 117
20.1 Company Overview 117
20.2 Value Chain Analysis 117
20.2.1 Manufacturing 118
20.2.2 Product Development 118
20.2.3 Sales and Marketing 118
20.3 Beckman Coulter, Inc. Pipeline Products 119
20.3.1 Beckman Coulter, Inc. Pipeline Products by Equipment Type 119
20.3.2 Beckman Coulter, Inc. Pipeline Products by Development Stage 120
20.3.3 Beckman Coulter, Inc. Pipeline Products by Therapy Area 121
20.3.4 Beckman Coulter, Inc. Pipeline Products by News Summary 121
21 Dade Behring Holdings, Inc. Company Profile 122
21.1 Company Overview 122
21.1.1 Dade Behring Holdings, Inc. Pipeline Products by Equipment Type 123
21.1.2 Dade Behring Holdings, Inc. Pipeline Products by Development Stage 123
21.1.3 Dade Behring Holdings, Inc. Pipeline Products by Therapy Area 123
21.1.4 Dade Behring Holdings, Inc. Pipeline Products by News Summary 123
22 Ortho-Clinical Diagnostics Inc. Company Profile 124
22.1 Company Overview 124
23 Ablynx NV Company Profile 125
23.1 Company Overview 125
24 Biocode Hycel Company Profile 126
24.1 Company Overview 126
25 BioTech Tools Company Profile 127
25.1 Company Overview 127
26 CorisBioConcept SPRL Company Profile 128
26.1 Company Overview 128
27 Euroscreen S.A. Company Profile 129
27.1 Company Overview 129
28 Immunosource Company Profile 130
28.1 Company Overview 130
29 Innogenetics NV Company Profile 131
29.1 Company Overview 131
30 International Brachytherapy S.A. Company Profile 132
30.1 Company Overview 132
31 Ion Beam Applications S.A. Company Profile 133
31.1 Company Overview 133
32 Appendix 134
32.1 Global Markets Direct Research Methodology 134
32.2 Coverage 135
32.3 Secondary Research 135
32.4 Primary Research 136
32.5 Models 136
32.6 Forecasts 137
32.7 Expert Panels 137
32.8 Currency Conversion 138
32.9 Contact Us 139
32.10 Disclaimer 139

Executive Summary

1.2 List of Figures
Figure 1: Total Healthcare Expenditure in Belgium, 2000 - 2006 22
Figure 2: Structure of Healthcare System in Belgium, 2007 27
Figure 3: Flowchart for Classification of Non-invasive Devices in Belgium, 2007 30
Figure 4: Flowchart for Classification of Invasive Devices in Belgium, 2007 31
Figure 5: Flowchart for Classification of Invasive Devices in Belgium, 2007 32
Figure 6: Flowchart for Classification of Invasive Devices in Belgium, 2007 33
Figure 7: Flowchart for Classification of Invasive Devices in Belgium, 2007 34
Figure 8: Flowchart for Classification of Active Devices in Belgium, 2007 35
Figure 9: Flowchart for Classification of Active Devices in Belgium, 2007 36
Figure 10: Flowchart for Classification of Devices except Non-invasive, Invasive and Active Devices in Belgium, 2007 37
Figure 11: Conformity Assessment of Class-I Medical Devices in Belgium, 2007 38
Figure 12: Conformity Assessment of Class-IIa Medical Devices in Belgium, 2007 39
Figure 13: Conformity Assessment of Class-IIb Medical Devices in Belgium, 2007 40
Figure 14: Conformity Assessment of Class-III Medical Devices in Belgium, 2007 41
Figure 15: In Vitro Diagnostics Cross Country Comparison (2000-2012) 45
Figure 16: In Vitro Diagnostics, Belgium, Overall Revenues ($ mn), 2000-2012 46
Figure 17: In Vitro Diagnostics, Belgium, Portfolio Analysis, 2000-2012 47
Figure 18: In Vitro Diagnostics, Belgium, Overall Revenues ($ mn), Historic, 2000-2007 48
Figure 19: In Vitro Diagnostics, Belgium, Overall Revenues ($ mn), Forecast, 2007-2012 50
Figure 20: In Vitro Diagnostics, Belgium Company share (%), 2007 52
Figure 21: Blood Test Reagents, Belgium, Revenue ($ mn) by Segment, Historic, 2000-2007 53
Figure 22: Blood Test Reagents, Belgium, Revenue ($ mn) by Segment, Forecast, 2007-2012 55
Figure 23: Haematology Test Reagents, Belgium, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007 57
Figure 24: Haematology Test Reagents, Belgium, Revenues ($ mn) by Sub-Segment, Forecast, 2007-2012 58
Figure 25: Hemostasis Test Reagents, Belgium, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007 59
Figure 26: Hemostasis Test Reagents, Belgium, Revenues ($ mn) by Sub-Segment, Forecast, 2007-2012 60
Figure 27: Blood Test Reagents, Belgium, Company Share (%), 2007 62
Figure 28: Clinical Chemistry Test Reagents, Belgium, Revenue ($ mn) by Segment, Historic, 2000-2007 63
Figure 29: Clinical Chemistry Test Reagents, Belgium, Revenue ($ mn) by Segment, Forecast, 2007-2012 64
Figure 30: Clinical Chemistry Test Reagents, Belgium, Company Share (%), 2007 66
Figure 31: Genetic Test Reagents, Belgium, Revenue ($ mn) by Segment, Historic, 2000-2007 67
Figure 32: Genetic Test Reagents, Belgium, Revenue ($ mn) by Segment, Forecast, 2007-2012 68
Figure 33: Genetic Test Reagents, Belgium, Company Share (%), 2007 70
Figure 34: Immunochemistry Test Reagents, Belgium, Revenue ($ mn) by Segment, Historic, 2000-2007 71
Figure 35: Immunochemistry Test Reagents, Belgium, Revenue ($ mn) by Segment, Forecast, 2007-2012 73
Figure 36: Disease Specific Markers, Belgium, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007 75
Figure 37: Disease Specific Markers, Belgium, Revenues ($ mn) by Sub-Segment, Forecast, 2007-2012 76
Figure 38: Disease Specific Test Reagents, Belgium, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007 77
Figure 39: Disease Specific Test Reagents, Belgium, Revenues ($ mn) by Sub-Segment, Forecast, 2007-2012 78
Figure 40: Drug Related Testing Reagents, Belgium, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007 79
Figure 41: Drug Related Testing Reagents, Belgium, Revenues ($ mn) by Sub-Segment, Forecast, 2007-2012 80
Figure 42: Hormone Related Testing Reagents, Belgium, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007 81
Figure 43: Hormone Related Testing Reagents, Belgium, Revenues ($ mn) by Sub-Segment, Forecast, 2007-2012 82
Figure 44: Immunochemistry Test Reagents, Belgium, Company Share (%), 2007 84
Figure 45: Infectious Immunology Test Reagents, Belgium, Revenue ($ mn) by Segment, Historic, 2000-2007 85
Figure 46: Infectious Immunology Test Reagents, Belgium, Revenue ($ mn) by Segment, Forecast, 2007-2012 87
Figure 47: Virology, Belgium, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007 89
Figure 48: Virology, Belgium, Revenues ($ mn) by Sub-Segment, Forecast, 2007-2012 90
Figure 49: Infectious Immunology Test Reagents, Belgium, Company Share (%), 2007 92
Figure 50: Instruments, Belgium, Revenue ($ mn) by Segment, Historic, 2000-2007 93
Figure 51: Instruments, Belgium, Revenue ($ mn) by Segment, Forecast, 2007-2012 94
Figure 52: Bacteriology Test Reagents, Belgium, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007 98
Figure 53: Bacteriology Test Reagents, Belgium, Revenues ($ mn) by Sub-Segment, Forecast, 2007-2012 99
Figure 54: Microbiology Test Reagents, Belgium, Company Share (%), 2007 101
Figure 55: Self Testing, Belgium, Revenue ($ mn) by Segment, Historic, 2000-2007 102
Figure 56: Self Testing, Belgium, Revenue ($ mn) by Segment, Forecast, 2007-2012 103
Figure 57: Self Testing, Belgium, Company Share (%), 2007 105
Figure 58: F. Hoffmann-La Roche Ltd Value Chain Analysis 106
Figure 59: Abbott Laboratories Value Chain Analysis 110
Figure 60: Biomerieux Sa Value Chain Analysis 114
Figure 61: Beckman Coulter, Inc. Value Chain Analysis 117
Figure 62: Global Markets Direct Methodology 134

F. Hoffmann-La Roche Ltd.
Abbott Laboratories
bioMerieux S.A.
Beckman Coulter, Inc.
Dade Behring Holdings, Inc.
Ortho-Clinical Diagnostics Inc.
Ablynx NV
Biocode Hycel
BioTech Tools
CorisBioConcept SPRL
Euroscreen S.A.
Immunosource
Innogenetics NV
International Brachytherapy S.A.
Ion Beam Applications S.A.

Customers who bought this item also bought

• Belgium In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
• Belgium In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
• Belgium In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2015
• Belgium Diagnostic Imaging Market Outlook to 2017 - Ultrasound Systems, MRI Systems, Computed Tomography Systems, Nuclear Imaging Equipment, X-Ray Systems, Mammography Equipment and Others
• Spain In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2012
• France In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2012
• Belgium Ophthalmic Devices Market Outlook to 2017 - Vision Care, Ophthalmic Diagnostic Equipment, Cataract, Refractive, Vitreo Retinal and Glaucoma Surgery Devices
• Australia In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2012
• Japan In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2012
• Europe In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2015